ISMP QuarterWatch Report From 2014 States Adverse Events Reports Show That Gilenya Cardiac Risks “were neither rare nor hypothetical”
SUMMARY: Last fall, from the September 24, 2014 edition of the ISMP QuarterWatch publication, we received more data and information about the various safety risks associated with Gilenya.
Given the extent and severity of the adverse events reports about Gilenya disrupting normal heart rhythm, we go into more depth on the cardiac-related risks associated with this still relatively new MS drug from Novartis. And from the September 2014 QuarterWatch from ISMP we get additional information about the heart-related problems patients have had when using Gilenya.
The safety profile for the Novartis drug Gilenya (fingolimod) has been controversial for some time now, and the concerns about adverse reactions and side effects continue.
We will continue to watch for reports of heart-related side effects with Gilenya and monitor the activity of drug regulators in the US, Canada, and Europe as regards the safety profile of this controversial Novartis MS drug.[Read this article in full at original source]
Strictly Confidential, No Obligation